Gail Horan
Lynn University
CancerInternal medicineRadiologySurgeryOncologyRandomized controlled trialSystemic therapyMedical physicsChemotherapyTomotherapyIfosfamideSarcomaMEDLINEProstate cancerBladder cancerMedulloblastomaRegimenCraniospinal IrradiationNuclear medicineConformal radiotherapyRadiation therapyClinical trialMedicine
49Publications
13H-index
429Citations
Publications 49
Newest
Source
#1Robert Huddart (ICR: Institute of Cancer Research)H-Index: 83
#2Shaista Hafeez (ICR: Institute of Cancer Research)H-Index: 13
Last. Hybrid InvestigatorsH-Index: 1
view all 24 authors...
Purpose Hypofractionated radiation therapy can be used to treat patients with muscle-invasive bladder cancer unable to have radical therapy. Toxicity is a key concern, but adaptive plan-of the day (POD) image-guided radiation therapy delivery could improve outcomes by minimizing the volume of normal tissue irradiated. The HYBRID trial assessed the multicenter implementation, safety, and efficacy of this strategy. Methods HYBRID is a Phase II randomized trial that was conducted at 14 UK hospitals...
8 CitationsSource
Source
#1Martin J. ConnorH-Index: 10
#2Taimur T. Shah (Imperial College London)H-Index: 14
Last. Hashim U. AhmedH-Index: 62
view all 36 authors...
Introduction Survival in men diagnosed with de novo synchronous metastatic prostate cancer has increased following the use of upfront systemic treatment, using chemotherapy and other novel androgen receptor targeted agents, in addition to standard androgen deprivation therapy (ADT). Local cytoreductive and metastasis-directed interventions are hypothesised to confer additional survival benefit. In this setting, IP2-ATLANTA will explore progression-free survival (PFS) outcomes with the addition o...
1 CitationsSource
#2Tom BoterbergH-Index: 31
Last. G.A. WhitfieldH-Index: 2
view all 11 authors...
Source
#2Tom BoterbergH-Index: 31
Last. Henry MandevilleH-Index: 14
view all 15 authors...
Source
#1Han Hsi Wong (Cambridge University Hospitals NHS Foundation Trust)H-Index: 3
#2Helen BentleyH-Index: 1
Last. Helen HatcherH-Index: 2
view all 7 authors...
Inflammatory myofibroblastic tumour (IMT) is a rare malignancy with limited responses to corticosteroids and chemotherapy. About half of cases have activating rearrangements in the ALK gene which could be targeted with ALK inhibitors. A 40-year-old man presented with a large right lung mass and nodal, trapezius and cerebral metastases. Biopsy confirmed IMT with TPM4-ALK fusion. He was treated with prednisolone without clinical benefit. He received the Trk/ROS1/ALK inhibitor entrectinib in a clin...
3 CitationsSource
#1Geert O. JanssensH-Index: 17
#2H. Mandeville (ICR: Institute of Cancer Research)H-Index: 1
Last. Tom Boterberg (Ghent University Hospital)H-Index: 31
view all 14 authors...
OBJECTIVE: To derive evidence-based recommendations for the optimal utilisation of resources during unexpected shortage of radiotherapy capacity. METHODS AND MATERIALS: We have undertaken a rapid review of published literature on the role of radiotherapy in the multimodality treatment of paediatric cancers governing the European practice of paediatric radiotherapy. The derived data has been discussed with expert paediatric radiation oncologists to derive a hierarchy of recommendations. RESULTS: ...
9 CitationsSource
#1Martin J. Connor (Imperial College London)H-Index: 10
#2Taimur T. Shah (Imperial College London)H-Index: 14
Last. Hashim U. Ahmed (Imperial College London)H-Index: 62
view all 20 authors...
TPS5600Background: Local cytoreductive and metastasis-directed interventions are hypothesised to confer additional survival benefit beyond standard systemic therapy in patients with de novo synchro...
1 CitationsSource
#1Martin J. Connor (Imperial College London)H-Index: 10
#2Taimur T. Shah (Imperial College London)H-Index: 14
Last. Hashim U. Ahmed (Imperial College London)H-Index: 62
view all 6 authors...
In the past decade, a revolution in the treatment of metastatic prostate cancer has occurred with the advent of novel hormonal agents and life-prolonging chemotherapy regimens in combination with standard androgen-deprivation therapy. Notwithstanding, the use of systemic therapy alone can result in a castrate-resistant state; therefore, increasing focus is being placed on the additional survival benefits that could potentially be achieved with local cytoreductive and/or metastasis-directed thera...
13 CitationsSource